Lymphadenectomy does not appear to decrease either mortality risk or disease recurrence in women with presumed stage I endometrial cancer, according to a Cochrane review of 2 trials involving nearly 2,000 women. The procedure was found to be linked with more severe adverse events. Among the specific findings:
- There is no evidence that women who received lymphadenectomy were less likely to die or have a relapse of their cancer (based on moderate quality evidence).
- Lymphadenectomy resulted in surgery-related morbidity and lymphoedema/lymphocyst formation (based on high quality evidence).
Frost J, Webster K, Bryant A, Morrison J. Lymphadenectomy for the management of endometrial cancer. Cochrane Database of Syst Rev. 2017, Issue 10. Art. No.: CD007585. doi:10.1002/14651858.CD007585.pub4.
This Week's Must Reads
ASCO Guideline on Alcohol Consumption and Cancer, J Clin Oncol; 2018 Jan; LoConte, Brewster, et al
Cochrane On Bisphosphonates for Prostate Cancer, Cochrane; 2017 Dec 26; Macherey, Monsef, et al
Cochrane on Vaccine-Based Immunotherapy for NSCLC, Cochrane; 2017 Dec 16; Zhu, Li, Tiselius, et al
Stereotactic Radiotherapy System Approved For BC, FDA news release; 2017 Dec 22
Perjeta Approved for Certain Type of Early BC, Genentech news release; 2017 Dec 20
Must Reads in Gynecologic Cancer
CD8+ Tumor-Infiltrating Lymphocytes and Ovarian Ca, JAMA Oncol; ePub 2017 Oct 12; OTTA Consortium
Lymph Node Removal During Endometrial Ca Surgery, Cochrane; 2017 Oct 2; Frost, Webster, et al
Cochrane on Reducing Neoplasia in Molar Pregnancy, Cochrane; 2017 Sep 11; Wang, Fu, Hu, et al
FDA Approves First Biosimilar to Treat Cancer, FDA news release; 2017 Sep 14
HPV vs Pap Test for Cervical Cancer Screening, Cochrane; 2017 Aug 10; Koliopoulos, Nyaga, et al